BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 2427948)

  • 1. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
    Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
    N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A prolonged-action somatostatin analog and carcinoid syndrome].
    Chayvialle JA
    Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
    Janson ET; Oberg K
    Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of the carcinoid syndrome with somatostatin, salmon calcitonin, or octreotide.
    Antonelli A; Gambuzza C; Bertoni F; Baschieri L
    Clin Ther; 1992; 14(2):178-84. PubMed ID: 1377097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of carcinoid syndrome with a somatostatin analogue].
    Döbrönte Z; Stöckert A; Végh G; Varga L
    Orv Hetil; 1992 Mar; 133(12):731-4. PubMed ID: 1372969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful symptomatic treatment of malignant carcinoid syndrome with the somatostatin analogue SMS 201-995.
    van Houten AA; Nortier JW; Vendrik CP
    Neth J Med; 1988 Apr; 32(3-4):194-8. PubMed ID: 2896307
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of somatostatin infusion in four patients with malignant carcinoid syndrome.
    Quatrini M; Basilisco G; Conte D; Bozzani A; Bardella MT; Bianchi PA
    Am J Gastroenterol; 1983 Mar; 78(3):149-51. PubMed ID: 6187212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
    Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
    Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A favorable response to the somatostatin analog SMS 201-995 in a patient with the carcinoid syndrome].
    Del Val A; Ponce J; Talens A; Martí-Bonmati L; Garrigues V; Berenguer J
    Rev Esp Enferm Dig; 1991 Mar; 79(3):215-7. PubMed ID: 2043408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of the administration of somatostatin 14 in the carcinoid syndrome. Clinical and biological study of 2 cases].
    Guillard JF; Galmiche JP; Chayvialle JA; Kremer M; Comoy E; Lerebours E; Charbonnel B; Colin R
    Gastroenterol Clin Biol; 1983 Dec; 7(12):1016-22. PubMed ID: 6141119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
    Rubin J; Ajani J; Schirmer W; Venook AP; Bukowski R; Pommier R; Saltz L; Dandona P; Anthony L
    J Clin Oncol; 1999 Feb; 17(2):600-6. PubMed ID: 10080605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes.
    Vinik AI; Tsai ST; Moattari AR; Cheung P; Eckhauser FE; Cho K
    Am J Med; 1986 Dec; 81(6B):23-40. PubMed ID: 2879447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin analogue phase I trials in neuroendocrine neoplasms.
    Anthony L; Johnson D; Hande K; Shaff M; Winn S; Krozely M; Oates J
    Acta Oncol; 1993; 32(2):217-23. PubMed ID: 7686764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
    Ruszniewski P; Ish-Shalom S; Wymenga M; O'Toole D; Arnold R; Tomassetti P; Bax N; Caplin M; Eriksson B; Glaser B; Ducreux M; Lombard-Bohas C; de Herder WW; Delle Fave G; Reed N; Seitz JF; Van Cutsem E; Grossman A; Rougier P; Schmidt W; Wiedenmann B
    Neuroendocrinology; 2004; 80(4):244-51. PubMed ID: 15627802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
    di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
    Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome.
    Moertel CG; Hanley JA
    Cancer Clin Trials; 1979; 2(4):327-34. PubMed ID: 93982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients.
    Ruszniewski P; Ducreux M; Chayvialle JA; Blumberg J; Cloarec D; Michel H; Raymond JM; Dupas JL; Gouerou H; Jian R; Genestin E; Bernades P; Rougier P
    Gut; 1996 Aug; 39(2):279-83. PubMed ID: 8977344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
    Guadalupe E; Deshpande HA; Stein SM
    Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
    Pavel M; Gross DJ; Benavent M; Perros P; Srirajaskanthan R; Warner RRP; Kulke MH; Anthony LB; Kunz PL; Hörsch D; Weickert MO; Lapuerta P; Jiang W; Kassler-Taub K; Wason S; Fleming R; Fleming D; Garcia-Carbonero R
    Endocr Relat Cancer; 2018 Mar; 25(3):309-322. PubMed ID: 29330194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial.
    Pavel M; Hörsch D; Caplin M; Ramage J; Seufferlein T; Valle J; Banks P; Lapuerta P; Sands A; Zambrowicz B; Fleming D; Wiedenmann B
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1511-9. PubMed ID: 25636046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.